Table 1.
Summary of the clinical information on the patients with rheumatoid arthritis
| BMI <20 | 20 < BMI <25 | BMI >25 | P value | |
|---|---|---|---|---|
| Clinical data | ||||
| Number | 16 | 46 | 19 | |
| Female (%) | 81.3% | 73.9% | 84.2% | |
| Age (years) | 56.9 ± 17.3 | 64.2 ± 11.0 | 59.3 ± 11.5 | ns |
| Disease duration (months) | 66.0 ± 110.1 | 72.4 ± 140.5 | 72.4 ± 171.1 | ns |
| DAS28esr | 4.67 ± 1.79 | 4.53 ± 1.33 | 4.93 ± 1.62 | ns |
| CDAI | 19.5 ± 12.9 | 17.4 ± 10.7 | 21.6 ± 16.1 | ns |
| HAQ | 0.87 ± 0.77 | 1.22 ± 0.92 | 1.39 ± 0.99 | ns |
| Anti-CCP antibody (%) | 87.5% | 84.7% | 89.4% | ns |
| RF (U/ml) | 145.3 ± 295.8 | 164.9 ± 311.3 | 445.1 ± 649.7 | 0.035* |
| MTX (mg/week) | 9.5 ± 2.5 | 9.0 ± 2.9 | 8.0 ± 3.11 | ns |
| PSL dose (mg/day) | 3.5 ± 4.1 | 3.6 ± 6.7 | 3.68 ± 3.89 | ns |
| bDMARDs (%) | 12.5% | 13.0% | 15.7% | ns |
Data are shown as mean +/− SD, unless stated otherwise. Differences were analyzed by one-way analysis of variance. Abbreviations: BMI body mass index, DAS disease activity score, CDAI Clinical Disease Activity Index, HAQ Health Assessment Questionnaire, CCP cyclic-citrullinated peptide, RF rheumatoid factor, MTX methotrexate, PSL prednisolone, bDMARD biological disease-modifying anti-rheumatic drug, ns not significant. *P < 0.05